Vallon Pharmaceuticals, Inc. (VLON)
Chart Events
Performance Outlook
| Previous Close | 0.5100 |
| Open | 0.5112 |
| Bid | 0.5012 x 3100 |
| Ask | 0.5100 x 1100 |
| Day's Range | 0.5056 - 0.5240 |
| 52 Week Range | 0.3400 - 10.3600 |
| Volume | |
| Avg. Volume | 3,429,909 |
| Market Cap | 5.362M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3640 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VLON
Related Research
- Vallon Pharmaceuticals Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat2 months agoMorningstar
- GlobeNewswire
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,700,000 s
- GlobeNewswire
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported additional results from the SEAL study evaluating the abuse potential of ADAIR. ADAIR is the Company’s proprietary abuse-deterrent formulation of immediate-release dextroam
- GlobeNewswire
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR
PHILADELPHIA, PA, May 11, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that the Japan Patent Office has granted Patent No. 7054709 titled, “Abuse Deterrent Formulations of Amphetamine,” covering ADAIR1, the Company’s proprietary abuse-deterre
